239 Days: Oncopeptides' Myeloma Drug Pepaxto Comes Off Market Just Months After Accelerated Approval

Withdrawal announcement marks shortest interval ever from accelerated approval to market removal after OCEAN confirmatory trial showed an adverse overall survival trend and US FDA said a hypothesis-generating subgroup analysis would need to be borne out in another study.

Sinking ship
An adverse survival trend in a confirmatory trial sank Pepaxto's chances of remaining on the market • Source: Alamy

Oncopeptides AB’s decision to pull the multiple myeloma drug Pepaxto (melphalan flufenamide) off the US market due to an adverse survival trend in the OCEAN confirmatory trial sets a new record for fastest time from US Food and Drug Administration accelerated approval to withdrawal.

The drug’s withdrawal was announced by Oncopeptides just 239 days after its accelerated approval in a heavily pretreated population of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet